18 Months of Dual Therapy for Chronic Hepatitis C Decreases Relapse Rate and Suggests New Treatment Approach for Hard to Treat Patients with Cirrhosis, Genotype 1, and High Baseline Viral load

[Guest guest]

NATAP - www.natap.org

Highlights from the 36th Annual Meeting of the European Association

for the Study of the Liver (EASL 2001)

April 18-22, 2001

Prague, Czech Republic

By Harvey S. Bartnof, MD

Staff Physician at AVERI, AIDS Virus Education and Research Institute

in San Francisco, CA.

Part 2

18 Months of Dual Therapy for Chronic Hepatitis C Decreases Relapse

Rate and Suggests New Treatment Approach for Hard to Treat Patients

with Cirrhosis, Genotype 1, and High Baseline Viral load

http://www.natap.org/2001/36theasl/part2easl042401.htm

__________________________________________________

[Guest guest]

NATAP - www.natap.org

Highlights from the 36th Annual Meeting of the European Association

for the Study of the Liver (EASL 2001)

April 18-22, 2001

Prague, Czech Republic

By Harvey S. Bartnof, MD

Staff Physician at AVERI, AIDS Virus Education and Research Institute

in San Francisco, CA.

Part 2

18 Months of Dual Therapy for Chronic Hepatitis C Decreases Relapse

Rate and Suggests New Treatment Approach for Hard to Treat Patients

with Cirrhosis, Genotype 1, and High Baseline Viral load

http://www.natap.org/2001/36theasl/part2easl042401.htm

__________________________________________________